Deal Description

The Company employs approx. 10 - 15 experienced and motivated FTEs. The company's products are characterised as medicinal pet food as they are regularly recommended by healthcare specialists. The company’s client portfolio is diversified: the combined top 10 clients only generate 10-15% of total revenue, including a loyal customer base. The company has a leading market position in its market segment, and an excellent reputation and a proven track record. The overall outlook of the business looks promising due to current market conditions, solid sustainable margins and long-term positive impact of COVID-19. The company’s current market of the Netherlands still offers ample growth opportunities. Furthermore, the unique recipe could easily be introduced in other countries, enabling revenue and EBITDA growth. Due to the competitive advantages of the business, it is one of the more expensive brands in its respectable segment. The history of the company has proven that lowering prices will automatically lead to an increase in revenue and EBITDA. An upward trends in EBITDA is expected due to (inter)national expansion, lowering prices and a focus on marketing. It is possible for the business to scale up production to approx. €7m revenue without large investments. The company gives an acquirer access to a well-diversified client portfolio, widely proven recipe and extraordinary margins. It provides a unique opportunity to enter the Dutch pet food industry and use the Company as a platform for geographical expansion. The Company presents excellent revenues with EBITDA margins of roughly 50%. The opportunities to scale up are widely available. For example, by expansion of the customer base and the entry to international markets. However, the current shareholder has other ambitions. Therefore, to realise the full potential of the Company, a sale of the shares in the company is considered. The Company could be a great fit for a strategic partner as well as a financial investor already involved in this market. 2021 (LE) Turnover c.€4.6m, EBITDA c.€2.3m. Please contact Sergio van Luijk from Cap Expand Partner in case of any questions (+32 474183088 / [email protected]).

No Files Attached